GSA Capital Partners LLP Takes $230,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

GSA Capital Partners LLP acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 970 shares of the medical research company’s stock, valued at approximately $230,000.

A number of other institutional investors have also modified their holdings of IQV. Canada Pension Plan Investment Board increased its stake in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares during the period. Farallon Capital Management LLC lifted its position in shares of IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares in the last quarter. Impax Asset Management Group plc boosted its position in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Legal & General Group Plc increased its stake in shares of IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock valued at $320,170,000 after acquiring an additional 11,715 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in IQVIA by 5.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,197,084 shares of the medical research company’s stock worth $253,125,000 after purchasing an additional 60,827 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

Shares of NYSE IQV opened at $201.82 on Monday. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a 50 day moving average of $222.67 and a 200-day moving average of $227.16. The company has a market capitalization of $36.63 billion, a P/E ratio of 26.49, a P/E/G ratio of 2.03 and a beta of 1.51.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on IQV shares. BTIG Research decreased their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Robert W. Baird cut their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.